Lacosamide Fresenius Kabi

Lacosamide, the active ingredient in Lacosamide Fresenius Kabi, is an anticonvulsant presented as an injectable solution for intravenous use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency and improve seizure control.\n\nGNH India supplies Lacosamide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic agent used in the management of seizure disorders.\n\nPartial‑onset seizures: reduces seizure frequency in patients with focal epilepsy.\nAdjunct therapy for refractory focal seizures: used as add‑on when seizures are not adequately controlled by other antiepileptic drugs.\nEpilepsy overall: contributes to overall seizure control as part of a comprehensive treatment regimen.

Lacosamide may cause a range of adverse reactions, which vary in frequency and severity.\n\nCommon Side Effects:\n- Nausea: mild to moderate gastrointestinal upset.\n- Dizziness: transient sensation of light‑headedness.\n- Headache: mild to moderate pain in the head region.\n- Somnolence: increased sleepiness or fatigue.\n- Blurred vision: temporary visual disturbances.\n- Fatigue: general feeling of tiredness.\n\nSerious or Rare Side Effects:\n- Cardiac arrhythmias: irregular heart rhythms, including PR‑interval prolongation.\n- Suicidal ideation: thoughts of self‑harm requiring immediate assessment.\n- Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.\n- Respiratory depression: reduced breathing effort, especially when combined with other depressants.\n- Anaphylaxis: rare but potentially life‑threatening allergic reaction.

When using Lacosamide, clinicians should consider several safety measures to minimize risk.\n\nMonitor cardiac function: observe for PR‑interval changes and arrhythmias.\nAdjust dose in renal impairment: reduce dosage in patients with decreased kidney function.\nAvoid abrupt discontinuation: taper gradually to prevent seizure recurrence.\nUse caution in hepatic disease: monitor liver enzymes and adjust dosing if needed.\nAssess for psychiatric symptoms: watch for mood changes or suicidal thoughts.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, affecting its efficacy or safety.\n\nMajor Interactions (Avoid):\n- Carbamazepine: may reduce lacosamide plasma levels.\n- Phenytoin: can lower lacosamide concentrations.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): increase lacosamide exposure.\n\nModerate Interactions (Monitor Closely):\n- Other antiepileptics (e.g., valproate): may require dose adjustments.\n- Serotonergic agents (e.g., SSRIs): monitor for serotonin syndrome.\n- Antihypertensives: observe for additive blood pressure effects.